Related Experiment Video
Updated: Jun 21, 2026
11:06
Subretinal Implantation of RPE on a Carrier in Minipigs: Guidelines for Preoperative Preparations, Surgical Techniques, and Postoperative Care
Published on: November 11, 2022
Ketorolac tromethamine formulations: an overview
V R Sinha1, R V Kumar, G Singh
1Panjab University, University Institute of Pharmaceutical Sciences, Chandigarh, India. sinha_vr@rediffmail.com
Expert Opinion on Drug Delivery
|August 12, 2009
Summary
Ketorolac tromethamine (KT), a potent NSAID, faces challenges due to gastrointestinal side effects and a short half-life. New formulations aim to improve its delivery for better efficacy and reduced adverse effects.
Area of Science:
- Pharmacology
- Drug Delivery Systems
- Medicinal Chemistry
Background:
- Ketorolac tromethamine (KT) is a non-steroidal anti-inflammatory drug (NSAID) belonging to heteroaryl acetic acid derivatives.
- It functions as a non-selective cyclooxygenase (COX) inhibitor, with the S-isomer retaining most analgesic and COX inhibitory activity.
- KT is available in various administration forms, including oral, intramuscular, intravenous, and topical ophthalmic solutions.
Purpose of the Study:
- To provide an overview of pharmaceutical formulation strategies for effective ketorolac tromethamine (KT) delivery.
- To highlight the development of novel dosage forms addressing KT's limitations.
- To emphasize the focus on sustained-release formulations for improved therapeutic outcomes.
Main Methods:
- Review of existing literature on ketorolac tromethamine (KT) formulation strategies.
- Analysis of concepts employed in designing diverse pharmaceutical dosage forms for KT.
- Examination of approaches for sustained drug release.
Main Results:
- Frequent gastrointestinal disturbances (bleeding, perforation, peptic ulceration) are associated with KT use.
- The short plasma half-life (approximately 5.5 hours) necessitates optimized delivery systems.
- Various formulation strategies have been explored to enhance KT's therapeutic efficacy and patient tolerance.
Conclusions:
- Development of advanced pharmaceutical dosage forms is crucial for effective ketorolac tromethamine (KT) delivery.
- Sustained-release formulations are a key focus for improving therapeutic efficacy and reducing gastrointestinal side effects.
- Optimized delivery systems can enhance the overall safety and tolerability profile of ketorolac tromethamine.
Related Concept Videos
01:23Ophthalmic Drug Delivery Systems
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
01:19Modified-Release Drug Delivery Systems: Overview
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...
01:27Drug Delivery Systems: Different Types
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
01:22Drug Delivery: Miscellaneous Routes
Drug delivery methods like oral inhalation, nasal sprays, transdermal patches, eye drops, intravitreal injection, and rectal administration provide localized effects with reduced toxicity.
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
Oral inhalation and nasal sprays swiftly transfer drugs across the respiratory epithelium's mucosal layer. Inhaled glucocorticoids and bronchodilators directly target lung conditions such as asthma, while fluticasone nasal spray mitigates allergic rhinitis.
Transdermal patches transport drugs through the...
01:26Oral Drug Delivery Systems: Continuous-Release Systems
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...